This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. British media are reporting that vaccinations with the human ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. For the record: An earlier version of this story and its headline ...

The FDA has approved Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant, from GlaxoSmithKline) for the prevention of cervical pre-cancers and cervical cancer associated ...

December 3, 2009 — The Cervarix vaccine, manufactured by GlaxoSmithKline, provides a high level of long-term protection against human papillomavirus (HPV) types 16 and 18. According to new data ...

GlaxoSmithKline PLC's Cervarix vaccine induced a higher immune response in women against the virus that causes cervical cancer than Merck & Co.'s Gardasil, according to a Glaxo-funded clinical ...

Until 2012, the vaccine in use was the bivalent Cervarix, targeting HPV 16 and 18. Then the quadrivalent Gardasil was administered until 2023, when the nonavalent Gardasil 9 was introduced.

Cervarix in UK, But Gardasil Elsewhere. The UK national program of HPV vaccination began last year, offering the vaccine through schools to all girls in the 12- to 13-year-old age range.

Cervarix, on sale in Australia, means that women too old for Gardasil can still be vaccinated -- provided they haven't already been exposed to HPV.

Cervarix: the simple injection causing so much controversy. The cervical cancer jab Cervarix is currently under scrutiny after nearly 1,500 Britons have experienced adverse reactions to it.

To date, CERVARIX(R) has been approved in more than 60 countries around the world including the 27 member countries of the European Union, Mexico, Australia, Singapore and the Philippines.

LONDON (MarketWatch) -- Drug maker GlaxoSmithKline PLC GSK Monday said Cervarix, a cervical cancer vaccine expected to become a multibillion-dollar product, has been approved by health regulators ...

Cervarix, which received marketing approval in the European Union earlier this week, is the first vaccine for the prevention of cervical cancer to be filed for approval in Japan.